THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 123 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is 3.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $121 | -14.8% | 14,069 | +2.5% | 0.00% | 0.0% |
| Q2 2023 | $142 | -16.0% | 13,723 | -11.8% | 0.00% | 0.0% |
| Q1 2023 | $169 | -99.8% | 15,565 | +35.1% | 0.00% | 0.0% |
| Q1 2022 | $110,000 | -4.3% | 11,525 | +10.6% | 0.00% | 0.0% |
| Q4 2021 | $115,000 | -50.6% | 10,423 | +8.6% | 0.00% | -50.0% |
| Q1 2018 | $233,000 | -44.0% | 9,599 | -35.7% | 0.00% | -33.3% |
| Q4 2017 | $416,000 | +274.8% | 14,931 | +205.5% | 0.00% | +200.0% |
| Q2 2016 | $111,000 | +68.2% | 4,887 | +40.2% | 0.00% | – |
| Q1 2016 | $66,000 | +73.7% | 3,486 | +51.3% | 0.00% | – |
| Q4 2015 | $38,000 | +11.8% | 2,304 | -25.9% | 0.00% | – |
| Q3 2015 | $34,000 | +183.3% | 3,108 | +229.2% | 0.00% | – |
| Q2 2015 | $12,000 | -7.7% | 944 | +28.8% | 0.00% | – |
| Q1 2015 | $13,000 | +18.2% | 733 | +0.5% | 0.00% | – |
| Q4 2014 | $11,000 | -45.0% | 729 | -16.0% | 0.00% | – |
| Q3 2014 | $20,000 | -28.6% | 868 | 0.0% | 0.00% | – |
| Q2 2014 | $28,000 | – | 868 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Woodford Investment Management Ltd | 10,898,879 | $264,297,000 | 23.51% |
| Foundation Asset Management, LP | 399,537 | $9,689,000 | 3.59% |
| Cormorant Asset Management, LP | 1,300,000 | $31,525,000 | 2.35% |
| Baupost Group | 9,309,168 | $225,747,000 | 2.18% |
| Old West Investment Management, LLC | 109,320 | $2,651,000 | 1.53% |
| SENZAR ASSET MANAGEMENT, LLC | 187,856 | $4,555,000 | 1.44% |
| Chescapmanager LLC | 350,631 | $8,503,000 | 1.27% |
| Virtus ETF Advisers LLC | 32,989 | $800,000 | 0.69% |
| Rock Springs Capital Management LP | 652,600 | $15,826,000 | 0.68% |
| NJ State Employees Deferred Compensation Plan | 34,142 | $828,000 | 0.15% |